
Edesa Biotech rose 18.0% from $1.70 to $2.00, ahead of the S&P 500's +4.7%. Its worst day was May 18 (−31.0%), and its low came Feb 20 at $0.80.
Nov 21, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.32 missed the $-0.27 estimate on $0.00 revenue.
−16.1% · S&P 500 −0.2%
EPS of $-0.28 beat the $-0.38 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
+0.5% · S&P 500 +0.2%
Edesa Biotech shares rose 90.8%, while the S&P 500 fell 0.9%.
+90.8%, the year's best day · S&P 500 −0.9%
Edesa Biotech shares rose 36.7%, while the S&P 500 rose 0.3%.
+36.7% · S&P 500 +0.3%
Edesa Biotech closed at its highest level of the year, 978.2% above where the year started.
+14.9% · S&P 500 +1.0%
EPS of $-0.49 missed the $-0.26 estimate on $0.00 revenue.
−10.7% · S&P 500 −1.2%
EPS of $-0.60 missed the $-0.44 estimate on $0.00 revenue.
−1.5% · S&P 500 −0.2%
Where it ended: a close of $2.00 on Nov 20, 2026. Up next: Q4 2026 earnings on Dec 11, 2026 (EPS est. $-0.58).
Nothing in the past 12 months.
All EDSA analyst actionsNothing in the past 12 months.
All EDSA dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for EDSA and SPY from Benzinga historical bars. Not investment advice.